CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient

Trastuzumab is regarded as the primary therapy for patients with HER2-enriched breast cancer, but the pathological complete response for advanced cases is less than 30%. The underlying mechanism of trastuzumab resistance remains unclear and there are currently no conclusive biomarkers for patient re...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yu-Chia, Li, Hao-Yi, Liang, Jui-Lin, Ger, Luo-Ping, Chang, Hong-Tai, Hsiao, Michael, Calkins, Marcus J., Cheng, Hui-Chuan, Chuang, Jiin-Haur, Lu, Pei-Jung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444696/
https://www.ncbi.nlm.nih.gov/pubmed/27447863
http://dx.doi.org/10.18632/oncotarget.10719

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444696/
https://www.ncbi.nlm.nih.gov/pubmed/27447863
http://dx.doi.org/10.18632/oncotarget.10719

Ejemplares similares